IPSWICH, Mass., Feb. 6, 2026 /PRNewswire/ — New England Biolabs (NEB ®) will present several scientific posters at this week’s Society for Laboratory AutomationIPSWICH, Mass., Feb. 6, 2026 /PRNewswire/ — New England Biolabs (NEB ®) will present several scientific posters at this week’s Society for Laboratory Automation

New England Biolabs ® Proudly Partners with Automation Providers to Support NGS Library Prep Automation Globally

2026/02/07 01:31
4 min read

IPSWICH, Mass., Feb. 6, 2026 /PRNewswire/ — New England Biolabs (NEB ®) will present several scientific posters at this week’s Society for Laboratory Automation and Screening (SLAS) meeting in Boston, MA, highlighting collaborations with leading laboratory liquid-handling automation providers, including Beckman Coulter Genomics, Eppendorf, Hamilton Company, Revvity, and SPT Labtech to support customer implementation of NEBNext® reagents for next-generation sequencing (NGS) library preparation.

According to Michael Benway, Sr. Automation Field Application Scientist for NEB, “As the manufacturer of reagents for NGS library prep, we seek to enable automation providers by working collaboratively on workflows and scripts for library prep methods that demonstrate equivalent or improved performance when executed on automated workstations. By leveraging the expertise of automation providers, we are then able to deploy the optimized methods globally to ensure customer success.”

NEB’s collaborative approach is built on close work with laboratory automation partners to automate, optimize and verify performance across a wide range of NEBNext products, including NEBNext UltraExpress® DNA and RNA Library Prep, NEBNext Enzymatic Methyl-seq (EM-seq™), and NEBNext Low-bias Small RNA Kits.

“Standardized, automation-ready workflows are critical for scaling NGS across organizations and geographies,” said Michael Mouradian, Vice President of Scientific Strategy and Market Development at Hamilton Company. “Our collaboration with NEB focuses on delivering robust, transferable methods that laboratories can deploy with confidence, while reducing implementation time and validation burden.”

According to Nicole Madamba, Sr. Manager of Research Applications at Revvity, “Our longstanding work with NEB has allowed us to apply our expertise to develop and deploy customer-centric automation solutions that we can support globally.”

Critical for the shift to portable, globally supported workflows is the standardization and optimization of hardware and software to ensure that solutions developed can be readily shared with customers, with minimal support required to customize and validate for specific customer needs.

Paul Lomax, Genomics Leader at SPT Labtech, “By applying software development principles to protocol design, we’ve transformed how we collaborate with NEB. This methodology allows us to build more robust NGS solutions that are instantly scalable and ready for immediate deployment across customer sites.”

The collaborative relationships between NEB and automation providers has been longstanding and customer-focused, delivering high-quality results for scientists worldwide, “Our partnership with NEB has always been driven by the shared goal of solving customer problems, and our collective commitment, leveraging both the Biomek and Echo liquid handlers, has empowered us to overcome some of the most significant challenges in automated NGS,” according to Ewan Grant, Senior Director, Automation Portfolio, Beckman Coulter Life Sciences.

Collaborative work being presented at the upcoming SLAS 2026 meeting includes:

Poster: 1360-A
NEBNext® UltraShear FFPE DNA Library Prep Kit Automated on Revvity Sciclone™ G3 NGSx Workstation

Poster: 1211-B
Automation of NEBNext® UltraExpress® DNA Library Prep Kit on Revvity Sciclone™ G3 NGSx Workstation with Low Input cfDNA in Collaboration with a Medical Research Institution

Poster: 1206-B
Automation and Verification of the NEBNext® Enzymatic Methyl-seq v2 (EM-seq v2) Library Preparation Workflow on the Revvity Sciclone™ G3 NGSx Workstation at the Yale Center for Genome Analysis

Poster: 1207-C
Automation of NEBNext® Ultra II FS using Unique Molecular Indexes with Revvity Sciclone™ G3 NGSx Workstation

Poster: 1209-E
Automation of NEBNext® Ultra™ II RNA Library Prep Kit for Illumina® and the NEBNext® Poly(A) mRNA Magnetic Isolation Module® on SPT LabTech firefly® Workstation at Weil Cornell Medical School Genomics Core

For more information and a list of available automation solutions for NEBNext products, please visit www.neb.com/automation

About New England Biolabs

For over 50 years, New England Biolabs (NEB) has pioneered the discovery and production of innovative products tailored for molecular biology research. Our commitment to scientific discovery is evident in all that we do, including our ever-expanding product portfolio, investment in our basic and applied research program, and support of customers’ research in academia and industry, including cutting-edge technologies for use in molecular diagnostics and nucleic-acid vaccines development. Guided by our founding principles, NEB proactively invests in efforts to improve the well-being of our employees, surrounding communities, as well as the future of our planet. NEB remains a privately held company with global reach, supported by our headquarters in Ipswich, MA, USA, subsidiary offices in 10 countries, and over 60 distribution partners around the world. For more information about New England Biolabs, visit www.neb.com.

NEW ENGLAND BIOLABS®, NEB®, NEBNEXT® and NEBNEXT ULTRAEXPRESS ® are registered trademarks of New England Biolabs, Inc.

Biomek and Echo Automated Workstations are not intended or validated for use in the diagnosis of disease or other conditions.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/new-england-biolabs–proudly-partners-with-automation-providers-to-support-ngs-library-prep-automation-globally-302681499.html

SOURCE New England Biolabs, Inc.

Market Opportunity
Mind-AI Logo
Mind-AI Price(MA)
$0,0001565
$0,0001565$0,0001565
+0,77%
USD
Mind-AI (MA) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Cashing In On University Patents Means Giving Up On Our Innovation Future

Cashing In On University Patents Means Giving Up On Our Innovation Future

The post Cashing In On University Patents Means Giving Up On Our Innovation Future appeared on BitcoinEthereumNews.com. “It’s a raid on American innovation that would deliver pennies to the Treasury while kneecapping the very engine of our economic and medical progress,” writes Pipes. Getty Images Washington is addicted to taxing success. Now, Commerce Secretary Howard Lutnick is floating a plan to skim half the patent earnings from inventions developed at universities with federal funding. It’s being sold as a way to shore up programs like Social Security. In reality, it’s a raid on American innovation that would deliver pennies to the Treasury while kneecapping the very engine of our economic and medical progress. Yes, taxpayer dollars support early-stage research. But the real payoff comes later—in the jobs created, cures discovered, and industries launched when universities and private industry turn those discoveries into real products. By comparison, the sums at stake in patent licensing are trivial. Universities collectively earn only about $3.6 billion annually in patent income—less than the federal government spends on Social Security in a single day. Even confiscating half would barely register against a $6 trillion federal budget. And yet the damage from such a policy would be anything but trivial. The true return on taxpayer investment isn’t in licensing checks sent to Washington, but in the downstream economic activity that federally supported research unleashes. Thanks to the bipartisan Bayh-Dole Act of 1980, universities and private industry have powerful incentives to translate early-stage discoveries into real-world products. Before Bayh-Dole, the government hoarded patents from federally funded research, and fewer than 5% were ever licensed. Once universities could own and license their own inventions, innovation exploded. The result has been one of the best returns on investment in government history. Since 1996, university research has added nearly $2 trillion to U.S. industrial output, supported 6.5 million jobs, and launched more than 19,000 startups. Those companies pay…
Share
BitcoinEthereumNews2025/09/18 03:26
Silver Price Crash Is Over “For Real This Time,” Analyst Predicts a Surge Back Above $90

Silver Price Crash Is Over “For Real This Time,” Analyst Predicts a Surge Back Above $90

Silver has been taking a beating lately, and the Silver price hasn’t exactly been acting like a safe haven. After running up into the highs, the whole move reversed
Share
Captainaltcoin2026/02/07 03:15
Citi Caps Year-End at $4,300, But ETF outflows Challenge Outlook

Citi Caps Year-End at $4,300, But ETF outflows Challenge Outlook

The post Citi Caps Year-End at $4,300, But ETF outflows Challenge Outlook appeared on BitcoinEthereumNews.com. Ethereum Price Prediction: Citi Caps Year-End at $4,300, But ETF outflows Challenge Outlook Disclaimer: The information found on NewsBTC is for educational purposes only. It does not represent the opinions of NewsBTC on whether to buy, sell or hold any investments and naturally investing carries risks. You are advised to conduct your own research before making any investment decisions. Use information provided on this website entirely at your own risk. Related News © 2025 NewsBTC. All Rights Reserved. This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy Center or Cookie Policy. I Agree Source: https://www.newsbtc.com/news/ethereum/ethereum-price-prediction-citi-caps-year-end-at-4300-but-etf-outflows-challenge-outlook/
Share
BitcoinEthereumNews2025/09/18 14:30